JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

Blood

Volumn 117, Issue 15, 2011, Pages 4056-4064

  Van Roosbroeck, Katrien ^a,b   Cox, Luk ^a,b   Tousseyn, Thomas ^c   Lahortiga, Idoya ^a,b   Gielen, Olga ^a,b   Cauwelier, Barbara ^d   De Paepe, Pascale ^d   Verhoef, Gregor ^c   Marynen, Peter ^a,b   Vandenberghe, Peter ^a   De Wolf Peeters, Chris ^c   Cools, Jan ^a,b   Wlodarska, Iwona ^a,e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d General Hospital St Jan   (Belgium)

^e CENTER FOR HUMAN GENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; JANUS KINASE 2; PROTEIN TYROSINE KINASE; STAT PROTEIN; VINBLASTINE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; CHROMOSOME ABERRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FUSION GENE; GENE REARRANGEMENT; GENE TRANSLOCATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IC 50; IMMUNOPHENOTYPING; KARYOTYPE; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL; TREATMENT RESPONSE;

EID: 79954606783     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-291310     Document Type: Article

References (52)

1. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281-1283. (Pubitemid 38559804)
2. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278(5341):1309- 1312. (Pubitemid 27495745)
3. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t (9; 12) in a lymphoid and t (9;15:12) in a myeloid leukemia. Blood. 1997;90(7):2535- 2540. (Pubitemid 27413461)
4. Reiter A, Walz C, Watmore A, et al. The t (8; 9) (p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65(7):2662-2667. (Pubitemid 40490065)
5. Griesinger F, Hennig H, Hillmer F, et al. A BCR-JAK2 fusion gene as the result of a t (9;22) (p24; q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer. 2005;44(3):329-333. (Pubitemid 41397102)
6. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from at (5;9) (q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer. 2008;47(10):884-889.
7. Mullighan CG, Morin R, Zhang J, et al. Next generation transcriptomic resequencing identifies novel genetic alterations in high-risk (HR) childhood acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group (COG) HR ALLTARGET Project [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):293-294. Abstract 704.
8. Nebral K, Denk D, Attarbaschi A, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(1):134-143.
9. Bousquet M, Broccardo C, Quelen C, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 2007;109(8):3417-3423. (Pubitemid 46572531)
10. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res. 2008;68(1):181-189. (Pubitemid 351380119)
11. Hitoshi Y, Lin N, Payan DG, Markovtsov V. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol. 2010;91(2):189-200.
12. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91(23):10962- 10966.
13. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101(4):1505-1512. (Pubitemid 36182527)
14. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
15. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25(18):2679-2684.
16. Hartmann S, Martin-Subero JI, Gesk S, et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica. 2008;93(9):1318-1326.
17. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60(3):549-552. (Pubitemid 30094549)
18. Meier C, Hoeller S, Bourgau C, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol. 2009;22(3):476-487.
19. Melzner I, Weniger MA, Menz CK, Moller P. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia. 2006;20(1):157-158.
20. Swerdlow A, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed. Lyon, France: International Agency for Research on Cancer; 2008.
21. Shaffer LG, Tommerup N. ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger AG; 2005.
22. Ensembl Genome Browser: Release 57, March 2010. http://www.ensembl.org. Accessed April 2010.
23. UCSC Genome Browser: NCBI37/mm assembly 7/07 update. http://genome.ucsc. edu. Accessed April 2010.
24. Van Roosbroeck K, Cools J, Dierickx D, et al. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica. 2010;95(3):509-513.
25. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
26. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBOJ. 1998;17(18):5321-5333. (Pubitemid 28427047)
27. Kelly LM, Liu Q, Kutok JL, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99(1):310-318.
28. Manshouri T, Quintas-Cardama A, Nussenzveig RH, et al. The JAK kinase inhibitor CP-690, 550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008;99(6):1265-1273. (Pubitemid 351695096)
29. Thompson JE, Cubbon RM, Cummings RT, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002;12(8):1219-1223. (Pubitemid 34270567)
30. Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100(1):238-245. (Pubitemid 35177453)
31. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
32. James C, Ugo V, Le Couedic JP, et al. Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemiavera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
33. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
34. Tang BL, Zhang T, Low DY, et al. Mammalian homologues of yeast sec31p. An ubiquitously expressed form is localized to endoplasmic reticulum (ER) exit sites and is essential for ER-Golgi transport. J Biol Chem. 2000;275(18):13597- 13604. (Pubitemid 30257427)
35. Yamasaki A, Tani K, Yamamoto A, Kitamura N, Komada M. The Ca2+-binding protein ALG-2 is recruited to endoplasmic reticulum exit sites by Sec31A and stabilizes the localization of Sec31A. Mol Biol Cell. 2006;17(11):4876-4887. (Pubitemid 44665756)
36. Bi X, Mancias JD, Goldberg J. Insights into COPII coat nucleation from the structure of Sec23. Sar1 complexed with the active fragment of Sec31. Dev Cell. 2007;13(5):635-645. (Pubitemid 350011990)
37. De Keersmaecker K, Rocnik JL, Bernad R, et al. Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. Mol Cell. 2008;31(1):134-142. (Pubitemid 351905920)
38. Stover EH, Chen J, Folens C, et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A. 2006;103(21):8078-8083. (Pubitemid 43801055)
39. Carron C, Cormier F, Janin A, et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood. 2000;95(12):3891-3899. (Pubitemid 30412865)
40. dos Santos NR, Ghysdael J. Atransgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia. Leukemia. 2006;20(1):182-185.
41. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood. 1999;94(9):3108-3113. (Pubitemid 29512717)
42. Aguilera NS, Chen J, Bijwaard KE, et al. Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens. Arch Pathol Lab Med. 2006;130(12):1772-1779. (Pubitemid 44906952)
43. Davis TH, Morton CC, Miller-Cassman R, Balk SP, Kadin ME. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med. 1992;326(17):1115-1122.
44. Kadin ME, Drews R, Samel A, Gilchrist A, Kocher O. Hodgkin's lymphoma of T-cell type: clonal association with a CD30+ cutaneous lymphoma. Hum Pathol. 2001;32(11):1269-1272. (Pubitemid 33104440)
45. Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191(2):387-394. (Pubitemid 30060928)
46. Seitz V, Hummel M, Marafioti T, et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood. 2000;95(10):3020-3024. (Pubitemid 30321149)
47. Tzankov A, Bourgau C, Kaiser A, et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol. 2005;18(12):1542-1549. (Pubitemid 41670652)
48. Willenbrock K, Ichinohasama R, Kadin ME, et al. T-cell variant of classical Hodgkin's lymphoma with nodal and cutaneous manifestations demonstrated by single-cell polymerase chain reaction. Lab Invest. 2002;82(9):1103-1109. (Pubitemid 35014843)
49. Willenbrock K, Kuppers R, Renne C, et al. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica. 2006;91(5):596-604. (Pubitemid 43799453)
50. Giglioni S, Leoncini R, Aceto E, et al. Adenosine kinase gene expression in human colorectal cancer. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):750-754. (Pubitemid 351948594)
51. Macleod RA, Nagel S, Drexler HG. BCL11B rearrangements probably target T-cell neoplasia rather than acute myelocytic leukemia. Cancer Genet Cytogenet. 2004;153(1):88-89. (Pubitemid 39592139)
52. Wakabayashi Y, Inoue J, Takahashi Y, et al. Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. Biochem Biophys Res Commun. 2003;301(2):598-603. (Pubitemid 36279283)